IWTI 2018 Video Series

Reimbursement Challenges and Solutions with Molecular Biomarker Testing

Video Library —December 18, 2018

Categories:

Interview with the Innovators
Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Related Articles
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, Emily Beard, RN, BSN, OCN, CBCN
|
Video Library
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
How Well Do Patients Tolerate Ovarian Function Suppression? Oncology Nurse Navigators Discuss Their Experience
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
This Interview with the Innovator video features breast cancer nurse navigators Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, as they discuss ovarian function suppression, how patients tolerate side effects, and educating patients on expectations of treatment.
Ovarian Suppression: What Are Some of the Important Questions That Women Ask?
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512